Otodac-DX Ear Drop is a combination pharmaceutical formulation containing Ofloxacin (0.3% w/v), a broad-spectrum fluoroquinolone antibiotic, and Dexamethasone (0.1% w/v), a potent corticosteroid. This preparation is indicated for the treatment of bacterial infections of the external auditory canal and middle ear, particularly otitis externa and otitis media, where inflammation and infection coexist. Ofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication and promoting eradication of susceptible pathogens. Concurrently, Dexamethasone provides anti-inflammatory action by suppressing the release of inflammatory mediators, reducing edema, erythema, and pain associated with ear infections. Otodac-DX is intended for topical administration into the ear canal, ensuring high local drug concentration with minimal systemic absorption. It is contraindicated in patients with hypersensitivity to quinolones, corticosteroids, or any component of the formulation, and should be used cautiously in cases of tympanic membrane perforation. Common adverse effects may include transient ear irritation or discomfort. Proper administration technique and adherence to prescribed dosage are essential to maximize therapeutic outcomes and minimize potential adverse reactions. Otodac-DX Ear Drop offers an effective dual-action approach for managing bacterial ear infections with inflammatory symptoms.